Step Pharma Highlights Innovative Research on CTPS2-Null Tumors
Step Pharma, a pioneering company in targeted cancer treatments, has announced remarkable findings in their research on CTPS2-null solid tumors. The Chief Scientific Officer, Philip Beer, is set to present this vital research at an approaching international conference dedicated to cancer therapeutics, showcasing the Company’s commitment to advancing the field of oncology.
Understanding the Breakthrough
During the upcoming conference, the focus will be on utilizing data from the AACR Project GENIE. This critical registry holds invaluable real-world clinico-genomic data, which led to identifying CTPS2 loss as a potential biomarker. The study finds that the deletion of CTPS2 is notably common across a spectrum of cancer types, particularly in ovarian cancer.
Targeting Tumor Dependencies
Research reveals that cancers originating from epithelial tissues are versatile in their metabolism, relying on both CTPS1 and CTPS2 for the final phase of CTP synthesis. When CTPS2 is absent, these tumors show a heightened reliance on CTPS1, marking a significant opportunity for targeted inhibition using Step Pharma’s innovative drug, dencatistat.
Precision Oncology Approach
Dencatistat, a highly effective oral inhibitor of CTPS1, is under evaluation in safety expansion studies aimed at patients with CTPS2-null cancers, with particular attention to ovarian cancer. This strategic approach exemplifies precision oncology at work, presenting promising avenues for treatment that could enhance the therapeutic efficacy of dencatistat.
Expert Insights
Philip Beer, Step Pharma’s CSO, emphasizes the importance of their findings. He notes, "Our exploration of clinico-genomic data indicates that patients with CTPS2-deleted solid tumors present a significant therapeutic target for dencatistat. With about 15-20% of ovarian cancers exhibiting this deletion, our aim is to finely tune our treatment strategies to optimize outcomes for these patients.”
Technical Session and Presentation Details
The presentation at the conference will be a part of the AACR Project GENIE session titled, "Powering Drug Discovery Through an International Consortium." Scheduled for Thursday, the focus will be on utilizing GENIE data to enhance oncology target identification and the development of therapeutic drugs.
About Step Pharma
Step Pharma was founded with a clear mission: to revolutionize cancer treatment through targeted therapies that effectively kill cancer cells while sparing healthy tissues. The Company’s expertise in CTPS1 inhibition positions it at the forefront of developing innovative cancer treatments aimed at both blood malignancies and solid tumors.
Founded by notable entities including Kurma Partners and the Imagine Institute, Step Pharma operates from Saint-Genis-Pouilly, France, backed by a committed group of investors. The Company continues to seek innovative pathways to address cancer, working tirelessly to bring about a transformative shift in clinical oncology.
Frequently Asked Questions
What is Step Pharma's primary focus?
Step Pharma specializes in targeting cancer with innovative therapies, particularly through the inhibition of CTPS1 to treat both solid tumors and blood cancers.
Who is presenting at the upcoming conference?
Philip Beer, the Chief Scientific Officer of Step Pharma, will present their groundbreaking research on CTPS2-null solid tumors.
What is dencatistat?
Dencatistat is an oral inhibitor of CTPS1 that Step Pharma is studying in cancer patients to provide a targeted treatment strategy.
Why is CTPS2 loss significant?
Loss of CTPS2 in tumors creates a dependency on CTPS1, making it a critical target for therapies like dencatistat in certain cancers.
Where can I find more information about Step Pharma?
More information about Step Pharma can be found on their official website at www.step-ph.com.
